Form 4 for GANX Gain Therapeutics, Inc.
Accepted 2023-12-22 00:00:00 ET · period of report 2023-12-20 · accession 0001209191-23-059558 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-22 | 2023-12-20 | GANX | Alder Matthias | CEO, Dir | M - OptEx | — | +637 | 5,492 | +13% | — |
| D | 2023-12-22 | 2023-12-21 | GANX | Alder Matthias | CEO, Dir | S - Sale+OE | $2.46 | -206 | 5,286 | -4% | -$506.76 |
| D | 2023-12-22 | 2023-12-20 | GANX | Alder Matthias | CEO, Dir | M - OptEx | $0.00 | -637 | 7,013 | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-20 | M | A | 637 | — | 5,492 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. |
| 2 | Common | Common Stock | 2023-12-21 | S | D | 206 | $2.46 | 5,286 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4602 to $2.485 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Restricted Stock Units | 2023-12-20 | M | D | 637 | $0.00 | 7,013 | D | — · — to — | 637 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. (F3) The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date. |